Remedy Robotics Raises $62 Million in Series B Funding
.png)
.png)
Remedy Robotics has raised $62 million in Series B funding.
Remedy Robotics has raised $62 million to bring AI-powered endovascular intervention to patients, wherever they are.
Cardiovascular diseases kill more people than all cancers combined and this funding will help us take important steps toward a world where every patient can access gold-standard endovascular treatment when they need it.
The round was led by DCVC, with participation from new investors including UC Investments (the University of California's investment office), Skip Capital and Hostplus. Existing investors Blackbird, Build Collective by Tony Fadell, Divergent Capital and KdT Ventures have each doubled down.
This funding will support the next stage of development for our AI-enabled N1 System, our AI-enabled robotic platform and software suite that uses machine learning to analyze preoperative imaging, simulate cases in advance, provide real-time 3D-2D image registration and complete entire endovascular procedures robotically. Designed for on-site, remote, or autonomous operation, the N1 has the potential to dramatically expand access to specialized neurovascular, coronary, and peripheral vascular care, while improving the standard of care for patients everywhere.
We're fortunate to have an incredible team, clinical partners and investors behind us. There's a lot of work ahead, and we're excited to get on with it.
You can read the full press release here.
If you would like to join us as we build the future of cardiovascular care, get in touch.


















